AAN Disease-Modifying Therapies For Adults With Multiple Sclerosis Guideline Summary - Guideline Central

Design and created by Guideline Central in participation with the American Academy of Neurology.

Document Overview

Document Title: Disease-Modifying Therapies For Adults With Multiple Sclerosis

Authoring Society: American Academy of Neurology

Document Publication Date: Apr 1, 2018

Page Last Reviewed/Updated: May 5, 2026

Document Type: Guideline

Country of Publication: United States

Full Text Freely Available: Yes

Full Text Guideline: cdn-links.lww.com/permalink/wnl/a/wnl_2018_04_19_raegrant_neurology2017835181r1_sdc3.pdf

Supplemental Implementation Resources

Document Scope, Criteria, and Use Cases

Document Objectives: To review evidence on starting, switching, and stopping disease-modifying therapies (DMTs) for multiple sclerosis (MS) in people with clinically isolated syndrome (CIS), relapsingremitting MS (RRMS), and progressive forms of MS; and to develop recommendations for starting, switching, and stopping DMTs

Scope: Treatment

Keywords: demyelinating autoimmune diseases, multiple sclerosis (MS), neuromyelitis optica

Inclusion Criteria: Male, Female, Adult, Older Adult

Health Care Settings: Ambulatory, Hospital, Outpatient

Intended Users: Nurse, Nurse Practitioner, Physician, Physician Assistant

Recommendation Development Processes & Methodology

Supplemental Methodology Resources: Methodology Supplement Methodology Supplement Methodology Supplement Methodology Supplement Systematic Review Document

Number of Source Documents: 227

Includes peer/external review process?: Yes

Includes public comment process?: No

Methodologist involvement?: Yes

Patient involvement?: No

Includes multi-disciplinary group?: Yes

Includes systematic review?: Yes

Grades quality of strength of evidence?: Yes

Grades quality of strength of recommendation?: Yes

Discloses funding source?: Yes

Discloses conflicts of interest?: Yes

Includes benefits/harms analysis with recommendations?: Yes